◎ Sugi Atlas

Atlas / Drug / ANTINEOPLASTON A10

ANTINEOPLASTON A10

drug
On this page

Also known as Antineoplaston a 10AtengenalSID489176

Summary

Antineoplaston A10 (CHEMBL1980825) is a phase-3 clinical-stage small molecule; indicated across 42 conditions including central nervous system cancer and colorectal adenocarcinoma.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Indications: 42 conditions
  • Clinical trials: 11
  • Chemistry: 246.26 Da · C13H14N2O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1980825
NameANTINEOPLASTON A10
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID56260
Molecular formulaC13H14N2O3
Molecular weight246.26
InChIKeyOQGRFQCUGLKSAV-JTQLQIEISA-N

SMILES: C1CC(=O)NC(=O)[C@H]1NC(=O)CC2=CC=CC=C2

IUPAC name: N-[(3S)-2,6-dioxopiperidin-3-yl]-2-phenylacetamide

Also known as: Antineoplaston a 10, Antineoplaston a10, Atengenal, SID489176, ANTINEOPLASTON A10

Patent coverage: 104 distinct patent families (299 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

38 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
central nervous system cancer2MONDO:0002714EFO:0000326
colorectal adenocarcinoma2MONDO:0005008EFO:0000365
mesothelioma2MONDO:0005065EFO:0000588
prostate adenocarcinoma2MONDO:0005082EFO:0000673
mantle cell lymphoma2MONDO:0018876EFO:1001469
gastric carcinoma2MONDO:0004950EFO:0000178
metastatic prostate carcinoma2MONDO:0004956EFO:0000196
astrocytoma (excluding glioblastoma)2MONDO:0019781EFO:0000272
carcinoma2MONDO:0004993EFO:0000313
glioblastoma2MONDO:0018177EFO:0000519
lymphoma2MONDO:0005062EFO:0000574
neoplasm2MONDO:0005070EFO:0000616
neuroblastoma2MONDO:0005072EFO:0000621
oligodendroglioma2MONDO:0016695EFO:0000632
small cell lung carcinoma2MONDO:0008433EFO:0000702
melanoma2MONDO:0005105EFO:0000756
plasma cell myeloma2MONDO:0009693EFO:0001378
anaplastic astrocytoma2MONDO:0016684EFO:0002499
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
brain neoplasm2MONDO:0021211EFO:0003833
primitive neuroectodermal tumor2MONDO:0005462EFO:0005235
rhabdoid tumor2MONDO:0002728EFO:0005701
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
head and neck cancer2MONDO:0005627EFO:0006859
Waldenstrom macroglobulinemia2MONDO:0100280EFO:0009441
ependymoma2MONDO:0016698EFO:1000028
adrenal cortex carcinoma2MONDO:0006639EFO:1000796
soft tissue sarcoma2MONDO:0018078EFO:1001968
brain cancer2MONDO:0001657MONDO:0001657
kidney cancer2MONDO:0002367MONDO:0002367
glioma2MONDO:0021042MONDO:0003268
breast neoplasm2MONDO:0021100MONDO:0007254
ovarian cancer2MONDO:0008170MONDO:0008170
lung neoplasm2MONDO:0021117MONDO:0008903
colonic neoplasm2MONDO:0005401MONDO:0021063
meningioma2MONDO:0016642MONDO:0016642
paraganglioma2MONDO:0000448EFO:1000453

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

PhaseTrials
PHASE29
PHASE32

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02864888PHASE3NOT_YET_RECRUITINGEffect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma
NCT02887040PHASE3NOT_YET_RECRUITINGStudy of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma
NCT00003455PHASE2WITHDRAWNAntineoplaston Therapy in Treating Women With Advanced Breast Cancer
NCT00003473PHASE2COMPLETEDAntineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
NCT00003485PHASE2TERMINATEDAntineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer
NCT00003486PHASE2WITHDRAWNAntineoplaston Therapy in Treating Patients With Colon Cancer
NCT00003502PHASE2WITHDRAWNAntineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma
NCT00003505PHASE2WITHDRAWNAntineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma
NCT00003514PHASE2WITHDRAWNAntineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
NCT00003517PHASE2WITHDRAWNAntineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
NCT00003536PHASE2WITHDRAWNMethotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 14

This page pulls from 14 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem